查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103004

轉錄組學診斷市場：策略性洞察與預測（2026-2035 年）

Transcriptomics Diagnostics Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

轉錄組學診斷市場預計將從 2026 年的 52.2 億美元成長到 2035 年的 138.9 億美元，複合年成長率為 11.5%。

轉錄組學診斷專注於分析RNA表現圖譜，以闡明疾病機制、識別生物標記、支持早期診斷並為個人化治療決策提供指南。與識別靜態DNA突變的基因組檢測不同，轉錄組學能夠即時洞察基因活性和細胞功能。 RNA定序（RNA-Seq）、微陣列、定量PCR（qPCR）、單細胞轉錄組學、人工智慧（AI）和基於雲端的生物資訊技術的進步，使得更全面的疾病表徵成為可能，並有助於改善臨床決策。隨著轉錄組學數據日益融入精準醫療項目，其在醫院、診斷實驗室、研究機構和製藥公司的應用正在加速發展。

市場促進因素

精準醫療的廣泛應用

醫療機構越來越依賴分子譜分析來制定個人化治療策略。轉錄組學診斷使臨床醫生能夠了解與疾病進展、治療反應和抗藥性相關的基因表現變化，從而支持個人化患者管理。

對基於RNA的生物標記的需求日益成長

RNA生物標記在疾病診斷、預後和治療監測中正變得越來越重要。轉錄組分析能夠實現疾病的早期檢測，並改善腫瘤學、神經病學、免疫學和感染疾病領域的患者分層。

定序技術的進步

次世代定序、定量PCR、單細胞RNA定序和生物資訊學平台的不斷進步顯著提高了轉錄組分析的速度、準確性和成本效益。這些創新正在拓展其在科學研究和臨床領域的應用。

加大基因組研究的投資

各國政府、醫療機構、製藥公司和學術組織繼續大力投資基因組學和轉錄組學研究，以加速生物標記發現、伴隨診斷和藥物發現。

市場限制因素

先進分子診斷技術高成本

全面的轉錄組分析需要先進的定序設備、實驗室基礎設施、計算資源和專業人員，這限制了其在小規模醫療機構中的應用。

複雜數據分析

由於轉錄組資料集會產生大量訊息，因此準確的臨床解釋需要先進的生物資訊學、人工智慧演算法和經驗豐富的分子病理學家。

監管和臨床驗證要求

在轉錄組檢測能夠常規地整合到診斷工作流程之前，臨床實施需要進行廣泛的檢驗、品質保證和監管批准。

目錄

第1章：執行摘要

  • 市場概述
  • 主要發現
  • 分析師意見
  • 策略建議

第2章：調查方法

  • 調查設計
  • 資料收集和調查方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章：轉錄組學診斷市場：概述、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 產業變化
  • 主要市場趨勢
  • 市場規模表現分析
  • 市場預測分析
  • 基因表現診斷生態系概述
  • 分子診斷工作流程概述
  • 測試數量分析
  • 用戶採納狀況分析
  • 轉錄組學診斷的臨床效用
  • 精準醫療和伴隨診斷的現狀

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 轉錄組學診斷領域的新興技術
  • 產品創新分析
  • RNA定序的進展
  • 空間轉錄組學創新
  • 多重基因表現技術
  • 臨床試驗分析
  • 管道分析
  • 將人工智慧整合到轉錄組數據分析中
  • 數位健康與生物資訊學的融合
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：轉錄組學診斷市場：展望分析

  • 分析：按技術平台
  • 分析：透過診斷技術
  • 分析：依生物標記類型
  • 分析：依樣本類型
  • 分析：透過臨床應用
  • 分析：透過測試環境
  • 分析：按最終用戶

第9章：轉錄組學診斷市場：細分市場分析

  • 按產品/服務
    • 裝置
    • 試劑和耗材
    • 軟體和生物資訊解決方案
    • 診斷檢測服務
  • 透過技術
    • RNA定序（RNA-Seq）
    • 逆轉錄PCR（RT-PCR）
    • 微陣列
    • 數位PCR
    • 空間轉錄組學
  • 依樣本類型
    • 組織樣本
    • 血液檢體
    • 其他生物檢體
  • 透過使用
    • 腫瘤學
    • 感染疾病
    • 罕見遺傳疾病
    • 神經病變
    • 自體免疫疾病
    • 心血管疾病
    • 其他用途
  • 最終用戶
    • 醫院和臨床檢查室
    • 參考實驗室
    • 學術研究機構
    • 製藥和生物技術公司
    • 其他最終用戶

第10章：轉錄組學診斷市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章：轉錄組學診斷市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 沙烏地阿拉伯

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 併購、合作與聯盟
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • 10x Genomics, Inc.
  • Standard BioTools Inc.
  • NanoString Technologies, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • Bruker Corporation
  • Merck KGaA
  • Takara Bio Inc.
  • Parse Biosciences, Inc.

第14章：轉錄組學診斷市場：商業預測分析

第15章：投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009008

The Transcriptomics Diagnostics Market is estimated to grow to USD 13.89 billion in 2035 at a CAGR of 11.5% from USD 5.22 billion in 2026.

Transcriptomics diagnostics focuses on analyzing RNA expression profiles to understand disease mechanisms, identify biomarkers, support early diagnosis, and guide personalized treatment decisions. Unlike genomic testing, which identifies static DNA alterations, transcriptomics provides real-time insights into gene activity and cellular function. Advances in RNA sequencing (RNA-Seq), microarrays, quantitative PCR (qPCR), single-cell transcriptomics, artificial intelligence (AI), and cloud-based bioinformatics are enabling more comprehensive disease characterization and improving clinical decision-making. Growing integration of transcriptomic data into precision medicine programs is accelerating adoption across hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies.

Market Drivers

Growing Adoption of Precision Medicine

Healthcare providers increasingly rely on molecular profiling to personalize treatment strategies. Transcriptomics diagnostics enables clinicians to understand gene expression changes associated with disease progression, therapeutic response, and drug resistance, supporting individualized patient management.

Rising Demand for RNA-Based Biomarkers

RNA biomarkers are becoming increasingly important for disease diagnosis, prognosis, and therapy monitoring. Transcriptomic profiling enables earlier disease detection while improving patient stratification across oncology, neurology, immunology, and infectious diseases.

Technological Advancements in Sequencing

Continuous improvements in next-generation sequencing, quantitative PCR, single-cell RNA sequencing, and bioinformatics platforms have significantly enhanced the speed, accuracy, and affordability of transcriptomic analysis. These innovations are expanding both research and clinical applications.

Increasing Investment in Genomic Research

Governments, healthcare organizations, pharmaceutical companies, and academic institutions continue investing heavily in genomics and transcriptomics research to accelerate biomarker discovery, companion diagnostics, and drug development.

Market Restraints

High Cost of Advanced Molecular Diagnostics

Comprehensive transcriptomic analysis requires sophisticated sequencing instruments, laboratory infrastructure, computational resources, and specialized personnel, limiting adoption in smaller healthcare facilities.

Complex Data Analysis

Transcriptomic datasets generate enormous volumes of information that require advanced bioinformatics, AI algorithms, and experienced molecular pathologists for accurate clinical interpretation.

Regulatory and Clinical Validation Requirements

Clinical implementation requires extensive validation, quality assurance, and regulatory approval before transcriptomic assays can be routinely incorporated into diagnostic workflows.

Market and Technology Insights

The global transcriptomics diagnostics market can be segmented by product & service, technology, application, end user, and geography.

By product & service, the market includes:

  • Instruments
  • Reagents & Consumables
  • Software & Bioinformatics Solutions
  • Diagnostic Testing Services

Reagents and consumables account for a substantial market share because of continuous demand across sequencing workflows, while bioinformatics software is experiencing rapid growth due to increasing adoption of AI-assisted analytics.

By technology, the market comprises:

  • RNA Sequencing (RNA-Seq)
  • Quantitative PCR (qPCR)
  • Microarrays
  • Single-Cell RNA Sequencing
  • Digital PCR
  • Other Transcriptomic Technologies

RNA sequencing represents the leading technology because of its ability to comprehensively analyze gene expression, while single-cell RNA sequencing is expanding rapidly through its ability to characterize cellular heterogeneity.

By application, the market includes:

  • Oncology Diagnostics
  • Infectious Disease Diagnostics
  • Neurological Disorders
  • Genetic Disorders
  • Precision Medicine
  • Companion Diagnostics

Oncology remains the largest application owing to increasing use of RNA signatures for tumor classification, biomarker identification, therapy selection, and disease monitoring.

By end user, the market serves:

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)

Hospitals and diagnostic laboratories continue expanding transcriptomic testing capabilities as precision diagnostics become more widely adopted.

Market Trends

The transcriptomics diagnostics market continues evolving through technological innovation.

Key trends include:

  • Increasing adoption of single-cell transcriptomics.
  • Expansion of AI-powered bioinformatics.
  • Growing integration of multi-omics diagnostics.
  • Rising development of companion diagnostics.
  • Expansion of cloud-based genomic analysis.
  • Increasing automation of laboratory workflows.
  • Growing utilization of liquid biopsy and RNA biomarkers.

Regional Insights

North America remains the largest market because of strong precision medicine initiatives, advanced molecular diagnostic infrastructure, substantial genomics research funding, and widespread adoption of RNA sequencing technologies.

Europe continues experiencing steady growth through expanding genomic medicine programs, increasing implementation of molecular diagnostics, and growing collaboration between research institutions and healthcare providers.

Asia-Pacific is expected to register the fastest growth owing to expanding healthcare infrastructure, increasing biotechnology investment, improving genomic research capabilities, and rising demand for personalized medicine. China, Japan, South Korea, India, and Australia are driving regional expansion.

Latin America and the Middle East & Africa are gradually strengthening molecular diagnostic capabilities through healthcare modernization, government investment, and international research collaborations.

Competitive Landscape

The market is characterized by continuous innovation in sequencing platforms, molecular diagnostics, bioinformatics, and AI-enabled analytical solutions.

Major companies include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Roche Diagnostics, Bio-Rad Laboratories, Standard BioTools (formerly Fluidigm), Oxford Nanopore Technologies, Pacific Biosciences (PacBio), 10x Genomics, NanoString Technologies, and BGI Genomics. Companies continue investing in RNA sequencing technologies, AI-powered interpretation platforms, integrated bioinformatics solutions, and strategic collaborations to strengthen their competitive positions.

Future Outlook

The future of the transcriptomics diagnostics market will be driven by broader implementation of precision medicine, increasing use of RNA biomarkers, continued advances in sequencing technologies, and growing integration of transcriptomics with multi-omics platforms. Improvements in automation, artificial intelligence, cloud computing, and single-cell analysis are expected to make transcriptomic diagnostics increasingly accessible for routine clinical applications while accelerating biomarker discovery and personalized treatment development.

Conclusion

The Global Transcriptomics Diagnostics Market is expected to witness robust growth through 2035, supported by increasing demand for precision diagnostics, expanding applications of RNA-based biomarkers, and continuous innovation in sequencing technologies. Although challenges related to implementation costs, bioinformatics complexity, and regulatory requirements remain, advances in transcriptomic technologies are expected to create significant opportunities for diagnostic manufacturers, biotechnology companies, healthcare providers, researchers, and investors.

Key Benefits of this Report

  • Comprehensive assessment of the global transcriptomics diagnostics market.
  • Detailed evaluation of technologies, applications, and emerging innovations.
  • Analysis of competitive strategies, technological developments, and commercialization opportunities.
  • Insights into precision medicine, RNA biomarkers, AI-enabled diagnostics, and companion diagnostics.
  • Valuable resource for diagnostic companies, biotechnology firms, healthcare providers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, precision medicine strategy, biomarker discovery, companion diagnostic development, commercialization planning, partnership evaluation, investment analysis, regulatory planning, and long-term strategic decision-making.

Report Coverage

  • Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global transcriptomics diagnostics market by Product & Service, Technology, Application, End User, and Geography
  • Evaluation of market dynamics, technology innovation, competitive landscape, regulatory environment, and future growth opportunities
  • Assessment of RNA sequencing, quantitative PCR, microarrays, single-cell RNA sequencing, oncology diagnostics, infectious disease diagnostics, precision medicine, companion diagnostics, AI-enabled bioinformatics, and commercialization strategies
  • Analysis of instruments, reagents & consumables, software & bioinformatics solutions, diagnostic services, hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, academic research institutes, and emerging transcriptomics diagnostic technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Transcriptomics Diagnostics Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Industry Overview
  • 3.3 Industry Evolution
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast Analysis (2026-2035)
  • 3.7 Gene Expression Diagnostics Ecosystem Overview
  • 3.8 Molecular Diagnostic Workflow Overview
  • 3.9 Testing Volume Analysis
  • 3.10 User Adoption Analysis
  • 3.11 Clinical Utility of Transcriptomics Diagnostics
  • 3.12 Precision Medicine and Companion Diagnostics Landscape

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies in Transcriptomics Diagnostics
  • 6.2 Product Innovation Analysis
  • 6.3 RNA Sequencing Advancements
  • 6.4 Spatial Transcriptomics Innovations
  • 6.5 Multiplex Gene Expression Technologies
  • 6.6 Clinical Trial Analysis
  • 6.7 Pipeline Analysis
  • 6.8 AI Integration in Transcriptomic Data Interpretation
  • 6.9 Digital Health and Bioinformatics Integration
  • 6.10 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Transcriptomics Diagnostics Market Landscape Analysis

  • 8.1 Analysis by Technology Platform
  • 8.2 Analysis by Diagnostic Technology
  • 8.3 Analysis by Biomarker Type
  • 8.4 Analysis by Sample Type
  • 8.5 Analysis by Clinical Application
  • 8.6 Analysis by Testing Setting
  • 8.7 Analysis by End User

9. Transcriptomics Diagnostics Market Segment Analysis (2021-2035)

  • 9.1 By Product & Service
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software & Bioinformatics Solutions
    • 9.1.4 Diagnostic Testing Services
  • 9.2 By Technology
    • 9.2.1 RNA Sequencing (RNA-Seq)
    • 9.2.2 Reverse Transcription PCR (RT-PCR)
    • 9.2.3 Microarrays
    • 9.2.4 Digital PCR
    • 9.2.5 Spatial Transcriptomics
  • 9.3 By Sample Type
    • 9.3.1 Tissue Samples
    • 9.3.2 Blood Samples
    • 9.3.3 Other Biological Samples
  • 9.4 By Application
    • 9.4.1 Oncology
    • 9.4.2 Infectious Diseases
    • 9.4.3 Rare Genetic Disorders
    • 9.4.4 Neurological Disorders
    • 9.4.5 Autoimmune Diseases
    • 9.4.6 Cardiovascular Diseases
    • 9.4.7 Other Applications
  • 9.5 By End User
    • 9.5.1 Hospitals & Clinical Laboratories
    • 9.5.2 Reference Laboratories
    • 9.5.3 Academic & Research Institutes
    • 9.5.4 Pharmaceutical & Biotechnology Companies
    • 9.5.5 Other End Users

10. Transcriptomics Diagnostics Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Transcriptomics Diagnostics Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 China
  • 11.8 Japan
  • 11.9 South Korea
  • 11.10 India
  • 11.11 Australia
  • 11.12 Brazil
  • 11.13 Saudi Arabia

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
  • 13.2 Illumina, Inc.
  • 13.3 Thermo Fisher Scientific Inc.
  • 13.4 QIAGEN N.V.
  • 13.5 Agilent Technologies, Inc.
  • 13.6 Bio-Rad Laboratories, Inc.
  • 13.7 10x Genomics, Inc.
  • 13.8 Standard BioTools Inc.
  • 13.9 NanoString Technologies, Inc.
  • 13.10 Oxford Nanopore Technologies plc
  • 13.11 Pacific Biosciences of California, Inc.
  • 13.12 Bruker Corporation
  • 13.13 Merck KGaA
  • 13.14 Takara Bio Inc.
  • 13.15 Parse Biosciences, Inc.

14. Transcriptomics Diagnostics Market Commercial Forecast Analysis

  • 14.1 Forecast by Instruments
  • 14.2 Forecast by Reagents & Consumables
  • 14.3 Forecast by Software & Bioinformatics Solutions
  • 14.4 Forecast by Diagnostic Testing Services
  • 14.5 Forecast by Oncology Diagnostics
  • 14.6 Forecast by Infectious Disease Diagnostics
  • 14.7 Forecast by Rare Disease Diagnostics
  • 14.8 Forecast by Spatial Transcriptomics Diagnostics

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends